Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KemPharm Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
KemPharm Enters into Licensing Agreement with Genco Sciences 11
KemPharm Enters into Licensing Agreement with Acura Pharma 12
Equity Offering 13
KemPharm Prices Public Offering of Shares for USD25 Million 13
KemPharm to Raise USD50 Million in Public Offering of Shares 15
KemPharm to Raise USD20 Million in Public Offering of Shares 16
KemPharm to Raise USD62.7 Million in Public Offering of Shares 17
KemPharm Raises USD56 Million in IPO 18
Debt Offering 20
KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 20
KemPharm Raises USD10 Million in Private Placement of Notes 22
Asset Transactions 23
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 23
KemPharm Inc – Key Competitors 24
KemPharm Inc – Key Employees 25
KemPharm Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 09, 2018: KemPharm reports second quarter 2018 results 27
May 10, 2018: KemPharm Reports Q1 2018 Results 29
May 10, 2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results 31
Mar 29, 2018: KemPharm Reports Fourth Quarter and Year End 2017 Results 34
Nov 09, 2017: KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update 36
Aug 10, 2017: KemPharm Reports Second Quarter 2017 Results 37
May 10, 2017: KemPharm Reports First Quarter 2017 Results 38
Mar 09, 2017: KemPharm Reports Fourth Quarter and Year End 2016 Results 39
Product News 40
11/16/2017: KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA 40
11/06/2017: KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511 41
07/09/2018: KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD 42
06/09/2017: KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids 44
05/10/2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug 45
03/20/2018: KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD 46
Product Approvals 47
Sep 20, 2017: KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate 47
Clinical Trials 48
Sep 11, 2018: KemPharm announces positive topline results from oral human abuse potential trial of KP415 prodrug 48
Jan 08, 2018: KemPharm Initiates Pivotal Efficacy Trial of KP415 49
Aug 10, 2017: KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial 50
Mar 16, 2017: KemPharm Presents Clinical Data for KP511 at American Academy of Pain Medicine’s Annual Meeting 51
Jan 09, 2017: KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain 52
Other Significant Developments 54
Oct 11, 2018: Kempharm provides highlights from KOL investor event focused on the ADHD treatment landscape 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
KemPharm Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
KemPharm Inc, Deals By Therapy Area, 2012 to YTD 2018 9
KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KemPharm Enters into Licensing Agreement with Genco Sciences 11
KemPharm Enters into Licensing Agreement with Acura Pharma 12
KemPharm Prices Public Offering of Shares for USD25 Million 13
KemPharm to Raise USD50 Million in Public Offering of Shares 15
KemPharm to Raise USD20 Million in Public Offering of Shares 16
KemPharm to Raise USD62.7 Million in Public Offering of Shares 17
KemPharm Raises USD56 Million in IPO 18
KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 20
KemPharm Raises USD10 Million in Private Placement of Notes 22
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 23
KemPharm Inc, Key Competitors 24
KemPharm Inc, Key Employees 25
KemPharm Inc, Other Locations 26
List of Figures
KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9